华兰生物工程股份有限公司 关于召开2023年第一次临时股东大会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 经华兰生物工程股份有限公司（以下简称"公司"）第八届董事会第八次会 议审议通过，公司将于2023年10月16日（星期一）召开2023年第一次临时股东大 会，现将有关事项通知如下： 证券代码：002007 证券简称： 华兰生物 公告编号：2023-027 一、召开会议的基本情况 1、股东大会届次：2023年第一次临时股东大会 2、股东大会的召集人：公司第八届董事会 3、会议召开的合法、合规性：本次股东大会会议召集符合有关法律、行政法 规、部门规章、规范性文件和《公司章程》的规定。 4、会议召开的日期、时间： （1）现场会议召开时间为：2023年10月16日下午14:30 （2）网络投票时间：2023年10月16日。其中通过深圳证券交易所交易系统进 行网络投票的具体时间为2023年10月16日上午9:15—9:25，9:30—11:30和下午 13:00—15:00；通过深圳证券交易所互联网投票的具体时间为2023年10月16日 09:15至15: ...

证券代码：002007 证券简称：华兰生物 公告编号：2023-028 华兰生物工程股份有限公司 关于独立董事公开征集委托投票权的公告 独立董事王云龙先生保证向本公司提供的信息内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 特别声明： 1、本次征集委托投票权为依法公开征集，征集人王云龙先生符合《中华人 民共和国证券法》第九十条、《上市公司股东大会规则》第三十一条、《公开征集 上市公司股东权利管理暂行规定》第三条规定的征集条件； 2、截至本公告披露日，征集人王云龙先生未直接或间接持有公司股票。 根据中国证监会《上市公司股权激励管理办法》（以下简称"《管理办法》"） 的有关规定，华兰生物工程股份有限公司（以下简称"公司"）独立董事王云龙 先生受其他独立董事的委托作为征集人，就公司拟于 2023 年 10 月 16 日召开的 2023 年第一次临时股东大会中审议的公司 2023 年限制性股票激励计划相关议案 向全体股东公开征集委托投票权。 一、征集人基本情况及声明 王云龙先生，中国国籍，无境外永久居留权， ...

华兰生物工程股份有限公司 | | | 获授限制 性股票数 | 占本激励计划授出 | 占本激励计划公告时 | | --- | --- | --- | --- | --- | | 姓名 | 职务 | | | | | | | 量（万 | 权益数量的比例 | 公司股本总额的比例 | | | | 股） | | | | 范蓓 | 董事、总经理 | 40 | 8.14% | 0.0219% | | 张宝献 | 董事、重庆公司 | 35 | 7.12% | 0.0192% | | | 总经理 | | | | | 马小伟 | 常务副总经理 | 30 | 6.10% | 0.0164% | | 潘若文 | 董事 | 25 | 5.09% | 0.0137% | | 谢军民 | 董秘、财务总监 | 20 | 4.07% | 0.0110% | | 刘俊 | 副总经理 | 15 | 3.05% | 0.0082% | | 陈正跃 | 副总经理 | 8 | 1.63% | 0.0044% | | 核心管理人员及核心技术 | | 268.5 | 54.63% | 0.1472% | | （业务）人员（77 | 人） | | | | | ...

附件 1 上市公司股权激励计划自查表 公司简称：华兰生物 股票代码：002007 | | 十三条、第二十九条规定的方法以外的其他方法确 | | | --- | --- | --- | | | 定授予价格、行权价格的，应当对定价依据及定价 | | | | 方式作出说明，聘请独立财务顾问核查并对股权激 | | | | 励计划的可行性、是否有利于上市公司的持续发展、 | | | | 相关定价依据和定价方法的合理性、是否损害上市 | | | | 公司利益以及对股东利益的影响发表明确意见并披 | | | | 露 | | | | （7）激励对象获授权益、行使权益的条件。拟分次 | | | | 授出或者行使权益的，应当披露激励对象每次获授 | | | | 或者行使权益的条件；对设立条件所涉及的指标定 | | | | 义、计算标准等的说明；约定授予权益、行使权益 | | | | 条件未成就时，相关权益不得递延至下期；如激励 | | | | 对象包括董事和高管，应当披露激励对象行使权益 | 是 | | | 的绩效考核指标；披露激励对象行使权益的绩效考 | | | | 核指标的，应充分披露所设定指标的科学性和合理 | | | | ...

Financial Performance - The company's operating revenue for the first half of 2023 was ¥1,585,241,916.69, a decrease of 32.53% compared to ¥2,349,403,299.73 in the same period last year[20]. - Net profit attributable to shareholders was ¥526,652,592.90, down 9.66% from ¥582,988,478.48 year-on-year[20]. - Basic earnings per share decreased to ¥0.2887, down 9.72% from ¥0.3198 in the same period last year[20]. - The company's total revenue for the reporting period was ¥1,585,241,916.69, a decrease of 32.53% compared to ¥2,349,403,299.73 in the previous year, primarily due to a reduction in vaccine sales volume[44]. - Blood products accounted for 90.25% of total revenue, with sales of ¥1,430,772,434.54, reflecting an increase of 11.68% year-on-year, while vaccine products saw a dramatic decline of 85.97% to ¥148,147,883.90[45]. - The net profit after deducting non-recurring gains and losses was ¥397,538,794.13, a decrease of 14.07% from ¥462,633,763.70 year-on-year[20]. - The company's gross profit margin for blood products was 53.72%, an increase of 1.18% compared to the previous year, while the gross profit margin for vaccines was 102.01% due to negative costs[47]. Cash Flow and Financial Position - The net cash flow from operating activities surged to ¥767,383,714.03, a significant increase of 6,440.70% compared to ¥11,732,435.25 in the previous year[20]. - The cash and cash equivalents decreased by 102.60% to a net reduction of ¥33,613,393.86, compared to an increase of ¥1,292,091,664.07 in the previous year[44]. - The company's total assets at the end of the reporting period were ¥14,492,806,740.67, a decline of 1.68% from ¥14,740,966,166.50 at the end of the previous year[20]. - The company's total liabilities decreased to ¥2,292,029,189.83 from ¥2,530,384,303.48, a reduction of approximately 9.4%[140]. - The company's total owner's equity was ¥12,200,777,550.84, slightly down from ¥12,210,581,863.02, a decrease of approximately 0.08%[140]. Research and Development - The company maintains a strong commitment to research and development in the biopharmaceutical sector, enhancing its competitive edge[28]. - Research and development expenses for the period were ¥146,124,153.48, a slight decrease of 2.73% from ¥150,222,277.92 in the previous year[44]. - The company has allocated approximately 1.5 billion yuan for research and development in 2023, which is a 10% increase from the previous year[161]. - The company is focusing on expanding its market presence and developing new products, although specific figures were not disclosed in the report[139]. Product Development and Market Strategy - The company is engaged in the research, production, and sales of blood products, vaccines, innovative drugs, and biosimilars, with a focus on high plasma utilization and a wide range of products[28]. - The company is developing innovative drugs and biosimilars, with Bevacizumab receiving drug registration acceptance and several others in clinical trials[29]. - The company aims to strengthen its core competitiveness by expanding strategic partnerships with domestic and international enterprises[36]. - The company plans to focus on market expansion and new product development in the upcoming quarters[146]. Environmental Management - The company has received various environmental approvals for its projects, ensuring compliance with environmental regulations and standards[75]. - The company has established a wastewater treatment facility with a capacity of 900m³/d and another facility in Chongqing with a capacity of 800m³/d, utilizing a treatment process of "hydrolysis acidification + AO + MBR biological membrane reactor" to meet discharge standards[81]. - The company has installed online monitoring equipment for wastewater discharge, ensuring real-time monitoring and timely response to any anomalies, maintaining long-term compliance with discharge standards without any exceedances[82]. - The company has committed to ongoing improvements in its environmental management practices to further reduce pollutant emissions and enhance sustainability[82]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period is 171,737[124]. - The largest shareholder, Ankang, holds 17.90% of the shares, totaling 326,527,406 ordinary shares[124]. - The company has not undergone any changes in its controlling shareholder or actual controller during the reporting period[128]. - The company did not conduct any repurchase transactions among the top 10 shareholders during the reporting period[126]. Risk Management - The company faces potential risks related to product safety, particularly concerning blood-derived products and vaccines, which could impact consumer trust and sales[63]. - The rising cost of raw plasma, which constitutes a significant portion of total production costs, poses a risk to the company's gross profit margin due to increasing donor compensation and competitive pricing pressures[64]. - The company is facing risks related to new product development, including potential delays or failures due to technical difficulties, policy changes, or market factors[65]. Corporate Governance - The financial report for the first half of 2023 has not been audited[136]. - The company confirms that its financial statements comply with accounting standards and accurately reflect its financial position, operating results, and cash flows[175]. - The company has evaluated its ability to continue as a going concern for the next 12 months and found no significant doubts regarding its sustainability[173].

机构名称：华兰生物工程股份有限公司夏邑单采血浆站 业务项目：机采单采普通原料血浆、机采单采破伤风免疫原料血浆、机采单 采狂犬免疫原料血浆、机采单采乙肝免疫原料血浆 许可证号：豫卫单采血浆站字〔2023〕第 9 号 采浆区域（范围）：夏邑县 证券代码：002007 证券简称：华兰生物 公告编号：2023-022 华兰生物工程股份有限公司 关于公司取得单采血浆许可证的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没 有虚假记载、误导性陈述或重大遗漏。 近日，华兰生物工程股份有限公司夏邑单采血浆站（以下简称"夏邑浆站"） 收到河南省卫生健康委员会印发的《单采血浆许可证》，主要信息如下： 有效期限：自 2023 年 8 月 10 日至 2025 年 8 月 9 日 夏邑浆站自取得《单采血浆许可证》之日起可正式采浆。夏邑浆站实现采浆 将有利于提升公司原料血浆供应能力，对公司长期发展具有积极作用。 特此公告。 华兰生物工程股份有限公司董事会 2023年8月15日 ...

证券代码：002007 证券简称：华兰生物 公告编号：2023-016 华兰生物工程股份有限公司 关于参加河南辖区上市公司 2023年投资者网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 为进一步加强与广大投资者的互动交流，华兰生物工程股份有限公司（以下 简称"公司"）定于2023年5月18日（周四）16:00-17:20参加在全景网举办的"真 诚沟通 传递价值"河南辖区上市公司2023年投资者网上集体接待日活动，本次 活动将采用网络远程方式举行，投资者可登录"全景·路演天下" （http://rs.p5w.net）参与本次互动交流。 出席本次网上集体接待日活动的人员有：公司财务总监兼董事会秘书谢军民 先生、证券事务代表娄源成先生，欢迎广大投资者积极参与！ 特此公告。 华兰生物工程股份有限公司董事会 2023年5月13日 ...

Financial Performance - The company's revenue for Q1 2023 was ¥880,663,132.35, representing a 37.46% increase compared to ¥640,654,562.67 in the same period last year[3]. - Net profit attributable to shareholders was ¥351,676,291.89, a 50.37% increase from ¥233,867,429.26 year-on-year[3]. - The company reported a basic earnings per share of ¥0.1928, up 50.16% from ¥0.1284 in the same quarter last year[3]. - The company reported a net profit of ¥336,700,119.97 for Q1 2023, compared to ¥250,000,000.00 in Q1 2022, marking a growth of 34.6%[14]. - The net profit for Q1 2023 was CNY 382,366,154.95, representing an increase of 63.5% compared to CNY 233,548,562.12 in Q1 2022[15]. - The total profit for Q1 2023 was CNY 452,776,994.23, which is a 63.5% increase from CNY 276,877,118.83 in Q1 2022[15]. - The company achieved a total operating profit of CNY 452,445,402.74, which is an increase from CNY 277,212,415.83 in the same quarter last year[15]. Cash Flow and Investments - The net cash flow from operating activities increased by 531.54%, reaching ¥369,227,788.51 compared to ¥58,464,293.99 in the previous year[3]. - The cash flow from operating activities netted CNY 369,227,788.51, a significant increase from CNY 58,464,293.99 in the same period last year[16]. - The company’s investment activities resulted in a net cash outflow of CNY 737,127,823.13, an improvement from a net outflow of CNY 917,424,055.81 in the previous year[16]. - The cash flow from financing activities showed a net outflow of CNY 4,710,975.73, compared to a net inflow of CNY 2,245,892,044.42 in Q1 2022[17]. Assets and Liabilities - Total assets at the end of the reporting period were ¥15,081,329,145.54, a 2.31% increase from ¥14,740,966,166.50 at the end of the previous year[3]. - The company's total assets as of the end of Q1 2023 were ¥15,081,329,145.54, compared to ¥14,740,966,166.50 at the beginning of the year, reflecting a growth of 2.3%[13]. - Current assets decreased to ¥7,788,606,531.76 from ¥8,077,183,237.37, a decline of 3.6%[11]. - The total liabilities at the end of Q1 2023 were ¥2,481,179,344.39, down from ¥2,530,384,303.48, indicating a reduction of 1.9%[12]. - The company’s total equity attributable to shareholders increased by 3.43% to ¥10,755,099,480.27 from ¥10,398,562,106.26 at the end of the previous year[3]. - The equity attributable to shareholders of the parent company increased to ¥10,755,099,480.27 from ¥10,398,562,106.26, a rise of 3.4%[13]. Expenses - Total operating costs for Q1 2023 were ¥543,963,012.38, up 39.4% from ¥390,032,981.03 in Q1 2022[14]. - Research and development expenses amounted to ¥77,578,545.59, representing a 21.7% increase from ¥63,757,662.28 in the previous year[14]. - The company experienced a 384.19% increase in sales expenses, attributed to higher service fees related to increased sales revenue[6]. Other Income and Gains - Investment income rose by 194.76%, primarily due to increased returns from financial products[6]. - The company reported a significant increase of 551.82% in fair value gains, driven by changes in the fair value of financial products[6]. - The company’s other comprehensive income attributable to shareholders was CNY 351,676,291.89, compared to CNY 233,867,429.26 in Q1 2022, marking a growth of 50.4%[15]. Future Outlook - The company plans to continue expanding its market presence and invest in new product development to drive future growth[14].

证券代码：002007 证券简称：华兰生物 公告编号：2023-010 (一)召开时间：2023年4月14日 15:00-17:00 (二)出席人员：公司总经理范蓓女士，财务总监、董事会秘书谢军民先生， 独立董事刘万丽女士。 (三)接入方式：投资者可登陆深圳证券交易所"互动易"平台 （http://irm.cninfo.com.cn），进入"云访谈"栏目参与本次说明会。 二、征集问题事项 为提升交流的针对性，以便公司在本次说明会上对投资者普遍关注的问题进 行作答，公司现就本次说明会提前向投资者公开征集问题，广泛听取投资者的意 见和建议。投资者可提前登录"互动易"平台，进入"业绩说明会提问预征集" 界面（http://irm.cninfo.com.cn/interview/collect/questionCollect），输 入公司股票代码后进行提问。届时公司将在本次说明会上对投资者普遍关注的问 题进行回答。欢迎广大投资者积极参与。 特此公告。 华兰生物工程股份有限公司 关于举行2022年度业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 华兰生 ...